JPRN-UMIN000049684已完成Unknown
Robust antibody response after the third mRNA coronavirus vaccination in Japanese hemodialysis patients - Robust antibody response to the third mRNA vaccine in dialysis patients
Fujita Memorial Hospital, Internal Medicine0 个研究点目标入组 294 人开始时间: 2022年12月4日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 294
研究概览
简要总结
After the third vaccination, 99.4% of the hemodialysis group and 100% of the control group were positive for antispike antibodies. Median antispike antibodies were 20,000 AU/mL (IQR, 7,729-37,000 AU/mL) in the hemodialysis group and 21,500 AU/ml (IQR, 14,000-32,250 AU/mL) in the healthcare worker group.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with a history of COVID-19 prior to study entry or with a positive blood test for anti-SARS-CoV-2 IgG antibodies at the time of study entry
研究者
相似试验
已完成
不适用
Humoral response after BNT162b2 vaccination in hemodialysis patientsChronic renal failure during hemodialysisJPRN-UMIN000047032Fujita Memorial Hospital294
已完成
不适用
Robust antibody response after 3 doses of mRNA COVID-19 vaccine in hemodialysis patientshemodialysis patientsJPRN-UMIN000047083Fujita Memorial Hospital283
已完成
2 期
COVID-19 Protection After Transplant Pilot StudyKidney Transplant RecipientsNCT04969263National Institute of Allergy and Infectious Diseases (NIAID)81
已完成
3 期
Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month ScheduleHepatitis BNCT00480116Henogen450
已完成
3 期
Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years OldInfluenzaNCT00617851Novartis Vaccines1,507